Month: September 2024

Barry’s Life: The Adventures and Travels of a Guy from Chicago and L.A. Dubbed as an “Ode to a Life Well-Lived”

Memoirs are truly beautiful. They give readers insight into the lives of individuals, condensing their experiences and lessons learned within a handful of pages. There is one particular title that is being dubbed as an “Ode to a life well-lived.” Author Barry Levitt presents his memoir Barry’s Life: The Adventures and Travels of a Guy from Chicago and L.A. The story spans from the Great Depression era in Chicago to the vibrant and bustling streets of Los Angeles. Through humor, wit, and a natural knack for storytelling, Levitt guides readers through his riveting experiences, anecdotes, and adventures that have made him who he is today.

Not only does Levitt paint a vivid picture of the changing times of the landscape growing up in Chicago, but also offers a glimpse into the broader social and historical context of the 20th century.

His daughters encouraged the author to preserve his stories for future generations as he embarked on a journey of writing his memoir and formulating this transformative book. Barry was a butcher who turned lawyer and CPA, traveling across all seven continents. His journey is incredibly inspiring, encouraging individuals to pursue their dreams. We also gain knowledge of Barry’s ancestors and the rich tapestry of his family’s history.

Mark, 21, a college student, had this to say about the book:

“Having grown up without a father, heading into college felt very overwhelming. I was afraid because, frankly, I thought that I had no one to watch over me. I had no wisdom to help me through the challenges that await me in life. Reading through Barry’s life, I felt as though he was speaking to me in a way. I found a father figure in the author, and it has helped me throughout my experience in college and personal life. Thank you, Barry, for this wonderful gift.”

Barry’s Life: The Adventures and Travels of a Guy from Chicago and L.A. is now available on Amazon.

About the Author

Meet Barry Levitt, a butcher turned lawyer and CPA who has traveled across all seven continents. Barry was born in 1931 and raised in Chicago during the Great Depression. Barry’s vivid storytelling captures the essence of a bygone era. Inspired by his daughters, Lisa and Renee, he began writing his memoir to share his life experiences and preserve his family’s legacy. Barry’s engaging anecdotes and humor make his stories relatable and captivating for readers of all ages.

For media inquiries, please contact:

Twitter: https://x.com/barrylevitt_

Facebook: https://www.facebook.com/profile.php?id=61561346947354

Instagram: https://www.instagram.com/authorbarry_levitt/# 

Amazon: https://a.co/d/ispyRfP

Media Contact
Company Name: Barry Levitt
Contact Person: Barry Levitt
Email: Send Email
City: New York
Country: United States
Website: a.co/d/ispyRfP

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Barry\’s Life: The Adventures and Travels of a Guy from Chicago and L.A. Dubbed as an \”Ode to a Life Well-Lived\”

HiWave Launches in Texas, Offering Affordable AI-Powered Personalized Videos for Businesses

September 16, 2024 – Texas – HiWave, a Texas-based startup, has launched a platform that blends AI with human creativity to help businesses create personalized video content quickly and affordably. HiWave’s customizable video templates allow companies to speed up video creation while keeping costs low. On average, businesses spend $5,000 to $20,000 on video production, but with HiWave, they can produce personalized, engaging videos starting at $3.

Personalized Communication at Scale

HiWave enables businesses to use personalized video content for various purposes, such as customer retention, sales, marketing, customer support, HR, and special occasions. 

Customers expect personalized communication in today’s digital landscape, and HiWave provides an affordable way to meet that demand. Research shows that 71% of consumers expect personalized interactions, and 52% are likely to switch brands if they don’t receive this experience. HiWave addresses these needs by helping businesses create more personalized videos and improving customer engagement.

Using AI and automation, HiWave generates unique videos tailored to each viewer. 

The platform offers businesses a selection of pre-made videos that can be quickly personalized with dynamic elements such as text, audio, images, or even video overlays. This customization makes the content more relevant and engaging for each recipient, helping businesses forge stronger connections with their audience. Whether creating a single video or thousands, the platform generates them in just minutes, streamlining the process and amplifying reach.

Building Deeper Connections

Ricky Flores, CEO of HiWave, emphasizes the importance of making business communications more meaningful. “We want to help businesses connect with their customers on a personal level, creating deeper, more genuine relationships through video,” said Flores.

HiWave’s platform is designed for fast production. By using AI and automation, businesses can create and deliver videos quickly, keeping pace with the rapid demands of the digital marketplace.

100% White-Label Video Templates

A standout feature of HiWave is its 100% white-label video templates. Businesses can create videos aligning with their brand identity, ensuring consistency while avoiding HiWave’s branding. This feature helps companies control their messaging while benefiting from HiWave’s technology.

The platform allows businesses to create high-quality, customized videos without the high costs typically associated with video production. This makes HiWave an essential tool for companies looking to improve their communication strategies and strengthen customer relationships.

Driving Business Growth

HiWave’s mission is to help businesses build stronger relationships through personalized communication. By offering an affordable, scalable solution, HiWave aims to set a new standard for video-driven business growth, assisting brands to improve customer engagement and drive success.

For more information, visit www.hiwave.ai

HiWave Media Relations

Email: contact@hiwave.ai

Phone: +1 (469) 554-9023

Media Contact
Company Name: Hiwave
Contact Person: Media Relations
Email: Send Email
Phone: +1 (469) 554-9023
Country: United States
Website: https://hiwave.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HiWave Launches in Texas, Offering Affordable AI-Powered Personalized Videos for Businesses

Efficient Shipping from China to Canada with Dantful International Logistics

“Shipping From China TO Canada”
The growth rate of bilateral trade between China and Canada has been impressive, with recent data indicating a year-on-year increase of approximately 15% in 2023, reaching a total trade value of $119.7 billion CAD. This surge highlights the increasing interdependence between the two economies and the potential for continued growth in various sectors.

Key industries driving this trade include electronics, machinery, and furniture, with China serving as a major supplier of these products to the Canadian market. Specifically, electronics, such as smartphones and computers, make up a significant portion of imports, while Canada exports valuable resources such as timber and agricultural products to China. The diversity of products exchanged underscores the importance of this trade relationship, making it essential for businesses to find reliable shipping partners to facilitate seamless transactions.

Dantful International Logistics stands out in this landscape as a highly professional freight forwarding service provider. With a commitment to excellence and a focus on customer satisfaction, Dantful offers a comprehensive suite of logistics services tailored for businesses looking to import goods from China to Canada. The company’s expertise in navigating the complexities of international shipping ensures that clients receive cost-effective and timely solutions, further enhancing their ability to compete in the global market.

1. Shipping Methods from China to Canada

When it comes to transporting goods from China to Canada, businesses have several shipping methods to choose from, depending on their specific needs, timelines, and budget. Each method offers distinct advantages and caters to different types of cargo, allowing importers to select the most suitable option for their logistics strategy.

Sea Freight from China to Canada

Sea Freight from China to Canada

Sea freight is the most popular and cost-effective method for shipping large volumes of cargo from China to Canada. This method is particularly advantageous for businesses looking to transport bulk goods, as it typically offers lower rates compared to air freight.

  • Cost-Effectiveness: Sea freight allows companies to save money, especially when shipping large quantities. This is due to the economies of scale that come with using a container ship, which can carry thousands of tons of cargo at once.

  • Types of Cargo: Sea freight is ideal for a wide range of products, including machinery, electronics, furniture, and raw materials. The shipping containers come in various sizes, including 20ft and 40ft, to accommodate different types of shipments.

  • Transit Time: The typical transit time for sea freight from China to Canada ranges from 20 to 30 days, depending on the specific route and any potential delays at ports. While it may be slower than air freight, many businesses find sea freight to be a reliable option for non-urgent shipments.

  • Environmental Impact: As a more sustainable shipping option, sea freight generally has a lower carbon footprint per ton of cargo compared to air freight, making it an environmentally friendly choice for companies looking to reduce their impact.

Air Freight from China to Canada

Air freight is the fastest shipping method available for transporting goods from China to Canada. This option is well-suited for businesses that require expedited delivery, such as seasonal products or urgent inventory replenishments.

  • Speed: With transit times ranging from 5 to 10 days, air freight is the best choice for time-sensitive shipments. This rapid service can significantly enhance supply chain efficiency, allowing businesses to respond quickly to market demands.

  • Cargo Limitations: While air freight is incredibly fast, it is also more expensive than sea freight. As a result, it is generally best suited for high-value or perishable items, such as electronics, pharmaceuticals, and fashion goods.

  • Security and Handling: Air freight offers enhanced security measures, making it a preferred choice for valuable shipments. Additionally, cargo handled by air freight often undergoes rigorous inspections, ensuring that items arrive safely and intact.

  • Flexibility: Air freight also provides increased flexibility in terms of shipping schedules, with multiple flights available to various destinations. This allows businesses to adjust their shipping plans according to their needs.

Door to Door Shipping from China to Canada

Door-to-door shipping is a comprehensive logistics solution that simplifies the process of importing goods from China to Canada. This method involves the entire shipping journey from the seller’s location in China to the buyer’s designated address in Canada, covering all logistics and customs clearance.

  • Convenience: One of the major advantages of door-to-door shipping is its convenience. Dantful International Logistics manages every aspect of the shipping process, including collection from the supplier, transportation, customs clearance, and delivery to the final destination.

  • Full-Service Offering: This shipping method often includes additional services such as packaging, insurance, and tracking, providing importers with a hassle-free experience and peace of mind.

  • Timeliness: While door-to-door shipping may take slightly longer than traditional methods, Dantful ensures timely delivery by coordinating all logistics seamlessly. The estimated time for door-to-door service can vary depending on the shipping method chosen (air or sea) but generally aligns with the aforementioned transit times.

  • Cost Considerations: Although door-to-door shipping may be higher in cost compared to basic shipping methods, the added convenience often justifies the expense for many businesses. It eliminates the need for multiple service providers and simplifies the logistics process.


How Long is Shipping from China to Canada?

Determining how long shipping from China to Canada will take depends largely on the chosen shipping method and various logistical factors involved in the process.

  • Ocean Freight: As mentioned earlier, shipping via ocean freight typically takes between 20 to 30 days. This timeframe includes the time it takes for the cargo to be loaded onto the vessel, the actual sailing time, and the customs clearance process upon arrival in Canada. Factors such as port congestion, weather conditions, and inspections can further influence transit times.

  • Air Freight: For those opting for air freight, the shipping duration is considerably shorter, ranging from 5 to 10 days. This method is ideal for urgent shipments, as it allows businesses to quickly replenish stock and meet customer demands.

  • Door-to-Door Shipping: The total time for door-to-door shipping will vary based on whether air or sea freight is used. If air freight is chosen, the total time may align with the 5 to 10 days mentioned. If sea freight is selected, the time frame would be closer to 20 to 30 days. The added convenience of door-to-door service ensures that all logistics are handled seamlessly, but businesses should remain mindful of the overall shipping duration based on their selected method.

By understanding the various shipping methods available and their respective timelines, businesses can make informed decisions that align with their logistics requirements and customer expectations.

Shipping Cost from China to Canada

When importing goods from China to Canada, understanding the shipping costs is essential for effective budget planning and overall logistics management. The cost of shipping can vary widely based on several key factors, including the shipping method, type of cargo, distance, and additional services required.

Factors Influencing Shipping Costs

  1. Shipping Method: The choice between sea freight and air freight significantly affects shipping costs. Generally, sea freight is more economical for larger shipments while air freight, although faster, tends to be substantially more expensive. Importers must assess their urgency and budget to choose the right method.

  2. Container Size: The size of the shipping container also plays a crucial role in determining costs. Standard container sizes include 20ft and 40ft, with costs varying accordingly. For example, shipping a 20ft container typically ranges from $1,200 to $2,500, while a 40ft container may cost between $2,000 and $4,500. Larger containers often provide better value for shipping heavier loads.

  3. Distance and Route: The geographical distance between the shipment’s origin in China and its destination in Canada influences shipping costs. Longer routes may incur higher fuel charges and handling fees, which can add to the overall shipping expense.

  4. Customs Duties and Taxes: Import duties, taxes, and applicable tariffs imposed by the Canadian government can significantly impact the total cost of shipping. It is crucial for businesses to be aware of these additional fees and incorporate them into their cost calculations.

  5. Additional Services: Additional services, such as insurance, customs clearance, and warehouse services, can also affect total shipping costs. For instance, opting for insurance can provide peace of mind for valuable shipments but will add to the overall expense.

Average Cost Estimates

Here is a brief overview of estimated shipping costs based on standard container sizes and shipping methods:

Average Cost Estimates Shipping from china to canada

These estimates provide a general guideline for businesses to assess their shipping costs when importing goods from China to Canada. By understanding these factors and averages, businesses can make informed decisions and effectively budget for their logistics needs.

Advantages of Dantful International Logistics

Dantful International Logistics is a premier freight forwarding service provider specializing in shipping from China to Canada. The company offers numerous advantages that make it an ideal partner for businesses navigating the complexities of international trade.

1. Comprehensive Logistics Solutions

Dantful provides a one-stop logistics solution, encompassing all aspects of shipping and supply chain management. Their services include:

  • Sea Freight and Air Freight: Offering both cost-effective ocean shipping and fast air transport options to meet varying client needs.

  • Customs Clearance: Expert assistance with documentation and compliance to ensure swift and efficient customs processing.

  • Warehouse Services: Flexible storage solutions tailored to businesses of all sizes, allowing for seamless inventory management.

2. Expert Knowledge and Experience

Dantful’s team comprises knowledgeable professionals with extensive experience in the logistics industry. Their expertise allows them to provide tailored solutions that address the unique challenges faced by businesses importing goods from China to Canada. Clients can trust that their shipments are managed by skilled personnel who understand the nuances of international shipping.

3. Cost-Effectiveness

With a commitment to providing cost-effective solutions, Dantful International Logistics helps clients optimize their shipping expenditures. By leveraging strategic partnerships with shipping lines and utilizing advanced logistics technologies, Dantful is able to offer competitive rates without sacrificing service quality. This focus on cost efficiency enables businesses to maximize their margins while enhancing their competitiveness in the market.

4. Commitment to Customer Service

Dantful places a strong emphasis on customer satisfaction. Their proactive approach ensures that clients receive timely updates and support throughout the shipping process. Whether it’s addressing concerns about transit times or providing detailed tracking information, Dantful is dedicated to maintaining open lines of communication and delivering exceptional service.

5. Flexible and Scalable Solutions

Whether a business is a small startup or a large corporation, Dantful offers scalable logistics solutions that adapt to the client’s evolving needs. This flexibility allows businesses to grow and expand their shipping capabilities without being constrained by rigid logistics structures.

By choosing Dantful International Logistics as a freight forwarding partner, businesses can benefit from a reliable, efficient, and cost-effective shipping solution tailored to their specific needs. With a focus on customer service, industry expertise, and comprehensive logistics offerings, Dantful stands out as a leader in international shipping from China to Canada.

Conclusion

In summary, navigating the complexities of shipping from China to Canada necessitates a solid understanding of various shipping methods, associated costs, and logistics strategies. Businesses must choose the right shipping option — whether sea freight, air freight, or door-to-door shipping — to align with their operational needs and budget. Understanding the influencing factors, such as container size, distance, and additional services, enables companies to make informed decisions that can significantly impact their cost-efficiency and overall success in international trade.

Dantful International Logistics stands out as a premier partner in this domain, offering comprehensive logistics solutions tailored to simplify the shipping process. With a strong commitment to customer satisfaction, expert knowledge, and cost-effective services, Dantful empowers businesses to confidently navigate the complexities of importing goods from China to Canada. By partnering with Dantful, companies can enhance their operational efficiency, optimize their supply chains, and ultimately thrive in the competitive global marketplace.

Media Contact
Company Name: Dantful International Logistics Co.,Ltd
Email: Send Email
Phone: +8613922898524
Address:Rm 8AB, Wenhua Building East Shennan East Rd
City: Shenzhen
State: Guangdong
Country: China
Website: https://www.dantful.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Efficient Shipping from China to Canada with Dantful International Logistics

Kelly Bagla Appointed to the Board of Directors of The Lincoln Club Business League

Kelly Bagla aka Queen of Business Law® is a renowned business executive and legal specialist.

Kelly Bagla, also known as “Queen of Business Law®,”  has been unveiled as the newest member of the board of The Lincoln Club Business League, where businesses flourish and communities prosper.  The Lincoln Club Business League fuels economic growth by backing business-friendly candidates and initiatives.

Elected officials, business executives, and entrepreneurs in San Diego come together through the Lincoln Club Business League, a prominent networking venue. The club supports efforts encouraging lower taxes, less regulation, and better economic prospects to foster a vibrant business climate. As a board member, Kelly will help direct the club’s initiatives to enhance the regional business climate by contributing her vast knowledge and enthusiasm for empowering companies.

Speaking to the media, Kelly Bagla stated, “We can make significant changes for our community as members of The Lincoln Club. I am thrilled to support initiatives that drive economic growth and empower business owners throughout San Diego. It is an honor to join this esteemed group.”

As evident, Kelly Bagla is regarded as one of the most significant corporate figures in San Diego. She has been recognized as a 2024 Top CEO nominee, a testament to her dedication to ethics, innovation, and moral corporate conduct. Kelly has over 20 years of legal experiance and has helped many business owners safeguard their operations, provide employment, and promote financial stability. Her knowledge extends beyond the practice of law as she actively assists entrepreneurs in reducing risks, averting litigation, and protecting their assets.

Her involvement in the community shows her dedication to giving back. Through the Veterans Chamber of Commerce, Kelly offers veterans pro-free legal services. She also fervently supports Last Chance At Life, an animal sanctuary that finds loving homes for sick canines. Her charitable endeavors demonstrate her commitment to having a good influence inside and outside the corporate sector.

Kelly will use her legal knowledge, entrepreneurial spirit, and commitment to the community as a board member of The Lincoln Club to support the club’s programs and encourage better cooperation in San Diego’s business sector.

Learn more at https://www.sdlincolnclub.com

For more information, reach out to Kelly Bagla, Queen of Business Law® at kelly@baglalaw.com or call 760-579-6789.

Address: 5857 Owens Ave Suite 300 Carlsbad, CA 92008 USA

 

Media Contact
Company Name: The Lincoln Club
Contact Person: Kelly Bagla, Queen of Business Law®
Email: Send Email
Phone: 760-579-6789
City: San Diego
State: California
Country: United States
Website: baglalaw.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kelly Bagla Appointed to the Board of Directors of The Lincoln Club Business League

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Size in the 7MM was ~USD 1,700 Million in 2023, estimated DelveInsight

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metabolic Dysfunction-Associated Steatohepatitis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Metabolic dysfunction-associated steatohepatitis (MASH), historical and forecasted epidemiology as well as the Metabolic dysfunction-associated steatohepatitis (MASH) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Metabolic Dysfunction-Associated Steatohepatitis Market by downloading the comprehensive report from DelveInsight @ Metabolic Dysfunction-Associated Steatohepatitis Therapeutics Market

 

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

  • In August 2024:- Corcept Therapeutics- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH). Approximately 120 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant or placebo twice weekly, for 48 weeks of treatment (Cohort A).
  • In August 2024:- Regeneron Pharmaceuticals- This study is researching an investigational drug called ALN-HSD (called “study drug”). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue).
  • The Metabolic Dysfunction-Associated Steatohepatitis Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
  • Based on DelveInsight’s estimates, the United States had the highest number of diagnosed prevalent cases of MASH in 2023, with a total of ~9.7 million cases. Following the US, EU4 and the UK had ~3.8 million cases, while Japan had ~2.6 million cases.
  • The categorization based on gender, showed that diagnosed prevalent cases in males were higher than in females in the 7MM. The male-diagnosed prevalent cases accounted for 56% of the total cases in the 7MM.
  • Japan accounted for approximately 16% of the total MASH Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase in the study period (2020–2034).
  • The leading MASH Companies such as Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
  • Promising MASH Therapies such as Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.

 

Gain a competitive edge in the Metabolic Dysfunction-Associated Steatohepatitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Drugs

 

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation in the 7MM

  • Metabolic Dysfunction-Associated Steatohepatitis Prevalent Cases
  • Metabolic Dysfunction-Associated Steatohepatitis Diagnosed Prevalent Cases
  • Metabolic Dysfunction-Associated Steatohepatitis Gender-specific Diagnosed Prevalent Cases
  • Metabolic Dysfunction-Associated Steatohepatitis Severity-specific Diagnosed Prevalent Cases

 

Metabolic Dysfunction-Associated Steatohepatitis Market Insights

MASH is a condition in which fat builds up in liver. It is the most common chronic liver disease, affecting at least a quarter of the global adult population. MASH is the progressive form of MASLD associated with persistent liver cell injury leading to fibrosis and in a subset may progress to cirrhosis and end-stage liver disease.

 

Discover key developments and opportunities in the Metabolic Dysfunction-Associated Steatohepatitis Market. Click here to learn more from DelveInsight’s latest report @ Metabolic Dysfunction-Associated Steatohepatitis Market Size

 

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

MASH treatment market marks a significant milestone in medical advancements, revolutionizing the landscape of MASH treatment. REZDIFFRA has emerged as a breakthrough therapy specifically designed to target the underlying mechanisms of MASH, offering new hope to patients suffering from this debilitating condition. Clinical trials have demonstrated remarkable efficacy in reducing MASH symptoms such as inflammation and fibrosis, while also improving overall liver function and patient quality of life. This approval has provided healthcare providers with a powerful tool to combat MASH disease, filling a critical gap in treatment options and potentially reducing the burden of complications associated with advanced liver disease.

 

Metabolic Dysfunction-Associated Steatohepatitis Marketed Drugs

  • REZDIFFRA (resmetirom): Madrigal Pharmaceuticals

REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). The emergence of the inaugural medication for MASH is a true game-changer for healthcare providers, the research community, and, most importantly, patients living with this serious liver condition. Based on the robust efficacy and safety data generated in two large Phase III MAESTRO studies, it is believed that REZDIFFRA will become the foundational therapy for patients with MASH with moderate to advanced liver fibrosis. As well as since now that the FDA has approved REZDIFFRA for MASH, pharmaceutical companies will have a better understanding of the thresholds they must meet to get future approvals.

 

Metabolic Dysfunction-Associated Steatohepatitis Emerging Drugs

  • Pegozafermin: 89bio, Inc

Pegozafermin or BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in MASH.

  • Efruxifermin (EFX): Akero Therapeutics, Inc.

Efruxifermin (EFX), is Akero’s lead product candidate for MASH. It is a differentiated Fc-FGF21 fusion protein engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treating MASH.

  • Belapectin: Galectin Therapeutics

Belapectin a complex carbohydrate drug, targets galectin-3, a critical protein in fatty liver disease and fibrosis pathogenesis. Galectin-3 plays a major role in organ scarring diseases, including the liver, lung, kidney, heart, and vascular systems fibrotic disorders. The drug binds to galectin-3 proteins and disrupts its function.

 

Metabolic dysfunction-associated Steatohepatitis Market Outlook

Until mid-March, the therapeutic landscape of NASH lacked FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments like diet and exercise. Supplemental interventions encompassed off-label usage of vitamin E and antidiabetic agents (e.g., pioglitazone, liraglutide) and liver transplantation in case of severe stages. Given NASH’s multifaceted pathogenesis, effective treatment demands comprehensive targeting of various cellular and molecular pathways.

 

Download DelveInsight’s Metabolic Dysfunction-Associated Steatohepatitis Market report today and stay ahead in this rapidly evolving field. @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

 

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

  • Coverage- 7MM
  • Metabolic Dysfunction-Associated Steatohepatitis Companies- Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
  • MASH Therapies- Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.
  • Metabolic Dysfunction-Associated Steatohepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Metabolic Dysfunction-Associated Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

 

Download the report to understand which factors are driving Metabolic Dysfunction-Associated Steatohepatitis Market Trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs

13. MASH: Market Analysis

14. Key Opinion Leaders’ Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 0650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Size in the 7MM was ~USD 1,700 Million in 2023, estimated DelveInsight

Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

“Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others”

 

The Tendonitis Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for o Tendonitis therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence

 

DelveInsight’s “Tendonitis Drugs Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Unlock detailed insights into the Tendonitis Market by downloading the comprehensive report from DelveInsight @ Tendonitis Therapeutics Market

 

Key Takeaways from the Tendonitis Market Report

  • The Growth of the Tendonitis Market is expected to be primarily driven by an expanding patient population, and advancement in diagnostic methods.
  • The leading Tendonitis Companies such as MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
  • Promising Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
  • As per the DelveInsight estimates, the total Tendinopathy Gender-specific cases in the United States was ~8,499,400 and 3,642,600 cases for males and females, respectively in 2022, which are expected to grow during the study period, i.e., 2019–2032.
  • In August 2024:- Wrightington, Wigan and Leigh NHS Foundation Trust- A Prospective, Double Blind, Single Centre, RCT, Comparing the Effectiveness of Physiotherapy in Addition to One of 3 Types of Image Guided Injection of the Common Extensor Tendon, on Pain and Function in Patients With Tennis Elbow.

 

Gain a competitive edge in the Tendonitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Tendonitis Treatment Drugs

 

Tendonitis Epidemiology Segmentation in the 7MM

• Total Tendonitis Incident Cases

• Tendonitis Type-specific Incident Cases

• Total Tendonitis Treated Cases

• Tendonitis Region-specific Incident Cases

• Tendonitis Gender-specific Incident Cases

 

Tendinopathy Treatment Market Landscape

The treatment landscape for tendinopathy is rapidly evolving, with numerous companies actively developing new therapies. Around 40-50% of patients currently undergo physiotherapy as part of their treatment. Recently, there’s been a surge in nutraceutical products that appear to support the healing of tendon injuries and may also serve as preventive measures. Although preclinical results are promising, the available literature on this topic remains limited. Managing tendinopathy with oral supplements is still a relatively new approach.

 

Tendinopathy Market Insights

Tendinopathy refers to a complex and multifaceted condition of the tendon, marked by pain, diminished function, and decreased exercise tolerance. The most frequently affected tendons due to overuse include the rotator cuff, medial and lateral elbow epicondyles, patellar, gluteal, and Achilles tendons. Key histological and molecular characteristics of tendinopathy include collagen fiber disorganization, increased microvasculature and sensory nerve innervation, disrupted extracellular matrix homeostasis, elevated immune cell activity and inflammatory mediators, and heightened cellular apoptosis.

 

Discover key developments and opportunities in the Tendonitis Market. Click here to learn more from DelveInsight’s latest report @ Tendonitis Market Size

 

Tendonitis Emerging Drugs

  • SI-613: Seikagaku Corporation

SI-613 is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound using Seikagaku’s own proprietary technology. SI-613 was designed to provide pain relief and anti-inflammatory effect by sustained release of NSAID, and the joint function improving effect by hyaluronic acid. It is expected to provide prompt and sustained relief of the severe pain and inflammation associated with osteoarthritis and enthesopathy. The drug is currently in phase II of clinical trials for the treatment of Tendonitis.

  • MP1032: MetrioPharm

MP1032’s mode of action – to accelerate the healing process – allows for the use of MP1032 as a therapeutic for Tendonitis before a tendinosis develops. In addition, MP1032 could accelerate the repair of already damaged tendons and thus also shorten the duration of tendinosis treatments. The drug is currently in phase I of clinical trials for the treatment of Tendonitis.

 

Tendinopathy Drugs and Companies

  • OCS-05 IV administration: Oculis
  •  BAT4406F Injection: Bio-Thera Solutions
  • Ravulizumab: Alexion Pharmaceuticals
  • B001: Shanghai Drug Research Development Co. Ltd.
  • Inebilizumab: Hansoh BioMedical R&D Company

 

Tendinopathy Market Dynamics

The dynamics of the Tendinopathy market are expected to evolve in the coming years. Preclinical models have supported this emerging therapeutic approach, but there is a notable lack of clinical studies involving stem cells for enhancing tendon repair or treating Tendinopathy, especially when compared to scaffolds and growth factors.

 

Download DelveInsight’s Tendonitis Market report today and stay ahead in this rapidly evolving field. @ Tendonitis Clinical Trials

 

Scope of the Tendonitis Market Report

  • Coverage- 7MM
  • Tendonitis Companies- MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
  • Tendonitis Therapies- TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
  • Tendonitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Tendonitis Unmet Needs, KOL’s views, Analyst’s views, Tendonitis Market Access and Reimbursement

 

Download the report to understand which factors are driving Tendonitis market trends @ Tendonitis Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Tendonitis

3. Competitive Intelligence Analysis for Tendonitis

4. Tendonitis: Market Overview at a Glance

5. Tendonitis: Disease Background and Overview

6. Patient Journey

7. Tendonitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Tendonitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Tendonitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tendonitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

Metastatic Prostate Cancer Treatment Market Size is expected to grow with a significant CAGR during the study period (2020-2034)

Metastatic Prostate Cancer Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metastatic Prostate Cancer Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Metastatic Prostate Cancer Market by downloading the comprehensive report from DelveInsight @ Metastatic Prostate Cancer Therapeutics Market

 

Key Takeaways from the Metastatic Prostate Cancer Market Report

  • In September 2024:- Bayer- The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC).
  • The Metastatic Prostate Cancer Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
  • Based on DelveInsight’s assessment in 2023, the 7MM had approximately 240,300 prevalent cases of metastatic prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024−2034).
  • Around 45% of all metastatic prostate cancer cases are attributed for mCSPC and ~55% accounted for mCRPC.
  • As per the estimates, in the US, majority of the cases were found to be localized/ locally advanced cases (Stage I-III), comprising approximately 60% of total cases, while nearly 32% belonged to biochemical recurrence/ progressive cases, and ~8% belonged to metastatic cases.
  • Prostate cancer is most frequently diagnosed among men aged 65–74 years. Analysis indicates that age-specific data differs across various geographic regions. In the US, prostate cancer was least prevalent among individuals aged over 84 years, whereas in Japan, the lowest number of cases were observed in the age group of 54 years or younger.
  • The leading Metastatic Prostate Cancer Companies such as AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
  • Promising Metastatic Prostate Cancer Therapies such as ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.

 

Gain a competitive edge in the Metastatic Prostate Cancer Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metastatic Prostate Cancer Treatment Drugs

 

Metastatic Prostate Cancer Epidemiology Segmentation in the 7MM

  • Total Prevalent Cases of Prostate Cancer in the US
  • Total Diagnosed Prevalent Cases of Prostate Cancer in the US
  • Age-specific Cases of Prostate cancer in the US
  • Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the US
  • Total Metastatic Cases of Prostate Cancer (mCSPC and mCRPC) in the US
  • Total Treated Cases of mCRPC in the US

 

Metastatic Prostate Cancer Treatment Market

The Metastatic Prostate Cancer treatment market landscape encompasses a diverse array of therapeutic options, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, ionizing radiation emitters, and others across various lines of treatment. The recent emergence of PARP inhibitors, particularly for patients harboring mutations in DNA damage repair genes, has expanded personalized treatment approaches and offered hope for improved outcomes.

 

Discover key developments and opportunities in the Metastatic Prostate Cancer Market. Click here to learn more from DelveInsight’s latest report @ Metastatic Prostate Cancer Market Size

 

Metastatic Prostate Cancer Marketed Drugs

  • NUBEQA (darolutamide): Bayer

NUBEQA (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, inhibiting the receptor function and the growth of prostate cancer cells.

NUBEQA is indicated for treating adult patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel.

  • ERLEADA (apalutamide): Janssen

ERLEADA is a next-generation oral androgen receptor inhibitor that blocks the androgen-signaling pathway in prostate cancer cells. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the androgen receptor, by stopping the androgen receptor from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell. It is indicated for treating patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

 

Emerging Metastatic Prostate Cancer Drugs

  • MGC018 (vobramitamab duocarmazine): MacroGenics

MGC018 (vobramitamab duocarmazine) is an investigational ADC comprised of a humanized B7-H3 mAb conjugated via a cleavable linker to the prodrug Seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA). MacroGenics began enrolling the TAMARACK Phase II study of vobramitamab duocarmazine (vobra duo) in patients with mCRPC under an amended protocol during the second quarter. This study is designed to evaluate vobra duo at two different doses, 2.0 mg/kg or 2.7 mg/kg every 4 weeks, across 100 patients. MacroGenics is also evaluating the activity of MGC018 plus lorigerlimab (an investigational PD-1 × CTLA-4 bispecific DART® molecule) in a Phase 1 study in patients with advanced solid tumors.

  • Bavdegalutamide (ARV-110): Arvinas

ARV-110 is an oral PROTAC protein degrader that targets the androgen receptor for potentially treating men with mCRPC and who have progressed on existing therapies. ARV-110 has demonstrated activity in preclinical models of androgen receptor mutation or overexpression, both common mechanisms of resistance to currently available androgen receptor-targeted therapies.

 

Metastatic Prostate Cancer Market Outlook

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a stage of prostate cancer that has spread to other parts of the body, such as lymph nodes or bones, and no longer responds to treatment that lowers testosterone. Despite currently approved therapeutics, mCRPC remains a terminal diagnosis with an aggressive disease course. ADT is a stalwart therapy for the initial treatment of metastatic disease. Unfortunately, most men in this situation will go on to develop mCRPC and require secondary systemic therapy. This disease state can be very challenging to treat.

 

Download DelveInsight’s Metastatic Prostate Cancer Market report today and stay ahead in this rapidly evolving field. @ Metastatic Prostate Cancer Clinical Trials

 

Scope of the Metastatic Prostate Cancer Market Report

  • Coverage- 7MM
  • Metastatic Prostate Cancer Companies- AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
  • Metastatic Prostate Cancer Therapies- ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.
  • Metastatic Prostate Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

 

Download the report to understand which factors are driving Metastatic Prostate Cancer Market Trends @ Metastatic Prostate Cancer Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary of Prostate Cancer

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Prostate Cancer Market Overview at a Glance

7 Disease Background and Overview

8 Treatment and Management of Prostate Cancer

9 Treatment Guidelines

10 Epidemiology and Patient Population

11 Patient Journey

12 Marketed Therapies

13 Emerging Therapies

14 Prostate Cancer: Seven Major Market Analysis

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Treatment Market Size is expected to grow with a significant CAGR during the study period (2020-2034)

Parainfluenza Virus Infection Treatment Market Size in the 7MM was ~USD 360 Million in 2023, estimates DelveInsight

Parainfluenza Virus Infection Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Parainfluenza Virus Infection Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Parainfluenza Virus Infection Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of parainfluenza virus infection, historical and forecasted epidemiology as well as parainfluenza virus infection market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Parainfluenza Virus Infection Market by downloading the comprehensive report from DelveInsight @ Parainfluenza Virus Infection Therapeutics Market

 

Key Takeaways from the Parainfluenza Virus Infection Market Report

  • As per DelveInsight analysis, it is estimated that the Parainfluenza Virus Infection treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development for the treatment of Parainfluenza Virus Infection Market Size and due to the increasing patient pool.
  • According to DelveInsight’s analysis in 2023, there were approximately 2,709,923 total incident cases of Parainfluenza Virus Infection in the 7MM. These cases are expected to increase by 2034 at a significant CAGR during the study period (2020–2034).
  • In 2023, the US accounted for approximately 1,456,399 incident cases of Parainfluenza Virus Infection. These cases are further expected to increase during the study period (2020-2034).
  • In 2023, Spain recorded the highest number of incident cases of PIV among EU4 and the UK, with nearly 257,254 cases. Germany followed with approximately 234,811 cases, while France reported around 190,245 cases. The incidence of Parainfluenza Virus Infection is projected to rise further during the forecast period.
  • The leading Parainfluenza Virus Infection Companies such as ModernaTX Inc., MedImmune LLC, Ansun Biopharma Inc., AlloVir, CyanVac LLC, QIAGEN Gaithersburg Inc., Novartis, Pfizer, Brazion Therapeutics, and others.
  • Promising Parainfluenza Virus Infection Therapies such as DAS181, ALVR106, and others.

 

Gain a competitive edge in the Parainfluenza Virus Infection Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Parainfluenza Virus Infection Treatment Drugs

 

Parainfluenza Virus Infection Prevalence

  • Total Incident Cases
  • Serotype-Specific Incident Cases
  • Gender-specific Incident Cases
  • Age-specific Incident Cases

 

Parainfluenza Virus Infection Market Insights

Most cases of PIV infections tend to resolve without requiring targeted medical treatment. Nonetheless, supportive strategies such as adequate rest, hydration, and the use of over-the-counter medications to relieve symptoms may be recommended. In severe cases or among individuals with weakened immune systems, antiviral medications or hospitalization may be necessary. Additionally, Ribavirin is sometimes administered off-label for treating PIV infections due to its in vitro activity. However, its effectiveness is subject to debate, as there is a lack of data from randomized trials.

 

Discover key developments and opportunities in the Parainfluenza Virus Infection Market. Click here to learn more from DelveInsight’s latest report @ Parainfluenza Virus Infection Market Size

 

Parainfluenza Virus Infection Treatment Market

The Parainfluenza Virus Infection Treatment Market addresses the growing demand for therapies that manage and mitigate infections caused by the human parainfluenza viruses (HPIVs). These viruses are a leading cause of respiratory illnesses, particularly in young children, the elderly, and immunocompromised individuals. While HPIVs can cause mild cold-like symptoms in some, they are known to lead to more severe conditions such as croup, bronchiolitis, and pneumonia.

 

Parainfluenza Virus Infection Market Outlook

The parainfluenza virus infection market outlook is expected to grow as the demand for more effective treatments and preventive measures continues to rise. Companies investing in novel antiviral therapies, immunotherapies, and vaccine research are likely to see significant opportunities in the coming years. Additionally, collaborations between pharmaceutical firms, research institutions, and government bodies may accelerate advancements in this field.

 

Download DelveInsight’s Parainfluenza Virus Infection Market report today and stay ahead in this rapidly evolving field. @ Parainfluenza Virus Infection Clinical Trials

 

Scope of the Parainfluenza Virus Infection Market Report

  • Coverage- 7MM
  • Parainfluenza Virus Infection Companies- ModernaTX Inc., MedImmune LLC, Ansun Biopharma Inc., AlloVir, CyanVac LLC, QIAGEN Gaithersburg Inc., Novartis, Pfizer, Brazion Therapeutics, and others.
  • Parainfluenza Virus Infection Therapies- DAS181, ALVR106, and others.
  • Parainfluenza Virus Infection Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Parainfluenza Virus Infection Unmet Needs, KOL’s views, Analyst’s views, Parainfluenza Virus Infection Market Access and Reimbursement

 

Download the report to understand which factors are driving Parainfluenza Virus Infection Market Trends @ Parainfluenza Virus Infection Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Parainfluenza Virus Infection (PIV) Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Emerging Therapies

11. Parainfluenza Virus Infection (PIV): Seven Major Market Analysis

12. Unmet Needs

13. SWOT Analysis

14. KOL Views

15. Reimbursement and Market Access

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parainfluenza Virus Infection Treatment Market Size in the 7MM was ~USD 360 Million in 2023, estimates DelveInsight

Re-imagine Fashion Show: A Groundbreaking Fusion of Fashion and Art Captivates New York Fashion Week

New York, NY – September 16, 2024 – Re-imagine, hosted by NotYetArt, produced by NotYetArt and FèY, is an extraordinary fashion and art event that redefined the boundaries of creativity and technology during New York Fashion Week. Held at 128 East 28th Street, New York, NY 10016, this exclusive showcase was a groundbreaking celebration of avant-garde fashion and experimental digital art. 

Re-imagine transcended the traditional fashion show format, offering attendees a visionary experience that seamlessly blended fashion with cutting-edge digital technology. The event highlighted a new frontier for artistic expression, capturing the imaginations of all who attended.

During the day, from 12pm-4pm, the showroom and art exhibition featured an eclectic array of innovative designs from renowned fashion brands, designers and artists, including Maison De Hoe, HSUX, MA.GI, Ying Ou, Jizhuo Li, SamStudio, DiChai (Lovers – Art Installation), Koi Ren & Joey Verbeke (In vivo/In vitro Trial 1.4 – Interactive Art), Rui Huang (Encapsulating Sensations – Digital Art), Ziyi Zhao (Emotion Tentacle – Sculpture), Xing Zhang (The Gaze – Illustration), and Alicia Zhu (Bodies – Photography). The space was abuzz with excitement as attendees engaged with these trailblazing creations, fostering vibrant discussions about the future of fashion and art.

The evening program, from 8 PM to 10:30 PM, kicked off with a groundbreaking digital fashion runway, featuring experimental fashion through interactive video and projections. This was followed by a live runway that showcased bold and imaginative designs from global visionary brands. The night’s highlights included a digital show curated by SamStudio and Lanyi Liu, and a live runway featuring collections from nine outstanding fashion designers, including Huayi Yang/KLORI, Zimeng Liu/LA FEZ, Jiahui Zhao/HUEY, Xinyi Hu/NEXGENESIS, Yutong Zhang/OOMPH MEN, Maggie Fan/MA.GI, Yinghan Qian, Zhouyi Wang, Xinran Fan. Additionally, Lei Qin/QIKE QILO presented an exquisite jewelry showcase, and Ying Ou displayed an impressive shoe collection.

Attendees explored immersive art installations, delving into the intersection of fashion and technology while rethinking traditional creative boundaries. The event provided ample networking opportunities, connecting designers, magazine editors, gallery managers, KOLs, and fashion buyers in a sophisticated setting. These vibrant exchanges facilitated important conversations and collaborations, highlighting the synergy between art and fashion.

Notable influencers in attendance included, but were not limited to, Justine Loffredo, Samir Sabe, Agen Xin, Kotryna Jukneviciute, April Zhang, and Damin Lee. The event received widespread acclaim across media platforms, solidifying Re-imagine as one of the most impactful independent fashion event during New York Fashion Week.

About Company:

NotYetArt is a global art co-creation community, dedicated to supporting emerging designers and fostering innovative artistic collaborations.

Presidents: Sichun Zhang & Yalin Hu

Team Acknowledgements:

  • Host and Co-production: NotYetArt Inc

  • Creative Direction and Co-Production: FèY

  • Casting and Styling：FèY

  • Venue and Lighting design：Jetta Lin

  • Graphic design：Alicia Zhu, Jetta Lin

  • Editor: Wenting Xu

Media Contact
Company Name: NotYetArt Inc
Contact Person: Sichun Zhang
Email: Send Email
Country: United States
Website: notyetarts.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Re-imagine Fashion Show: A Groundbreaking Fusion of Fashion and Art Captivates New York Fashion Week

Introducing “Keys to Your Property”: A New Informative Real Estate Blog Offering Expert Advice for Home Sellers, Buyers, and Investors

Baltimore, MD – Sep 16, 2024 – Real estate expert Tariq Thomas, founder of the well-regarded home-buying company Yes I Pay Cash – We Buy Houses, is proud to announce the launch of his latest venture: an informative real estate blog titled “Keys to Your Property.” This new blog aims to provide practical advice and valuable insights to home sellers, buyers, and investors, leveraging Tariq’s over 20 years of experience in the real estate industry.

“Keys to Your Property” offers a unique perspective on the real estate market, drawn from Tariq Thomas’s extensive experience as both a real estate investor and a licensed agent. From practical tips on selling a home quickly to in-depth analysis of market trends, the blog is designed to be a go-to resource for anyone involved in real estate.

A Resource Built on Decades of Real Estate Experience

Tariq Thomas’s journey in the real estate world began in 2002, buying his first investment property and quickly expanding his portfolio across Maryland, Pennsylvania, and New Jersey. As the founder of the Thomas Holding Group and Yes I Pay Cash, Tariq has developed a deep understanding of the complexities involved in real estate transactions, renovations, and creative financing strategies. His new blog, “Keys to Your Property,” encapsulates this knowledge, providing readers with actionable advice and real-life examples from his career.

“My goal with ‘Keys to Your Property’ is to offer straightforward, reliable advice that can help people navigate the often confusing world of real estate,” said Tariq Thomas. “Whether you’re a first-time home seller, an experienced investor, or someone looking to buy a home, there’s something here for everyone.”

Content That Speaks to the Needs of the Real Estate Community

The blog is structured to cover a wide range of topics, including:

  • Home Selling Tips: Strategies for selling homes quickly and efficiently, including tips on staging, pricing, and marketing.

  • Home Buying Guidance: Insightful advice on choosing the right property, understanding market trends, and negotiating the best deals.

  • Investor Insights: Strategies for real estate investors, from identifying lucrative opportunities to managing properties and understanding the market.

  • Market Analysis: Regular updates on market trends and forecasts, helping readers stay informed about the latest real estate developments.


Providing Transparency and Creating Win-Win Scenarios

“Keys to Your Property” reflects Tariq’s commitment to transparency and his belief in creating win-win scenarios in real estate transactions. Through the blog, he aims to educate readers about alternative methods to buying and selling homes, including options that go beyond traditional routes.

About Tariq Thomas

Tariq Thomas is a seasoned real estate investor and licensed agent with over two decades of experience in the industry. Having started his career in New Jersey and New York, Tariq moved to Maryland in 2004, where he established the Thomas Holding Group of Maryland. Following the 2009 market crash, he founded Yes I Pay Cash – We Buy Houses — a reputable home-buying company operating in Maryland, Pennsylvania, Delaware, and New Jersey. Tariq’s passion for real estate, his transparent approach, and his dedication to helping homeowners find the best solutions are at the heart of his new blog, “Keys to Your Property.”

Get Informed, Stay Ahead with “Keys to Your Property”

To learn more about “Keys to Your Property” and explore its rich collection of articles, visit https://keystoyourproperty.com/. Whether you’re a seasoned investor or just starting your real estate journey, “Keys to Your Property” has something for everyone.

Media Contact
Company Name: Keys to Your Property
Contact Person: Bill
Email: Send Email
Country: United States
Website: https://keystoyourproperty.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Introducing \”Keys to Your Property\”: A New Informative Real Estate Blog Offering Expert Advice for Home Sellers, Buyers, and Investors